Indian breast cancer study tracks gene mutations and drug response
NCT ID NCT05022342
First seen Jan 02, 2026 · Last updated May 14, 2026 · Updated 18 times
Summary
This study was done in India to learn more about a gene change called PIK3CA in people with a specific type of advanced breast cancer (HR-positive, HER2-negative). It also looked at how well the drug alpelisib worked for those with the gene change. About 595 people took part, but no new treatments or tests were given—doctors made all decisions as usual. The goal was to gather information, not to test a new cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Hyderabad, Andhra Pradesh, 500034, India
-
Novartis Investigative Site
Guwahati, Assam, 781023, India
-
Novartis Investigative Site
Kochi, Kerala, 682041, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400071, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 440001, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 441108, India
-
Novartis Investigative Site
Pune, Maharashtra, 411004, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110060, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110092, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751003, India
-
Novartis Investigative Site
Bhubaneswar, Odisha, 751007, India
-
Novartis Investigative Site
Chandigarh, Punjab, 160055, India
-
Novartis Investigative Site
Ludhiana, Punjab, 141008, India
-
Novartis Investigative Site
Jaipur, Rajasthan, 302017, India
-
Novartis Investigative Site
Sherilingampally, Telangana, 500019, India
-
Novartis Investigative Site
Howrah, West Bengal, 711103, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700029, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700054, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700063, India
-
Novartis Investigative Site
Ahmedabad, 380054, India
-
Novartis Investigative Site
Kanpur, 208002, India
-
Novartis Investigative Site
Kolkata, 700016, India
-
Novartis Investigative Site
Kolkata, 700026, India
-
Novartis Investigative Site
Kolkata, 700107, India
-
Novartis Investigative Site
Puducherry, 605006, India
-
Novartis Investigative Site
Udaipur, 313011, India
Conditions
Explore the condition pages connected to this study.